IN2014DN09678A - - Google Patents
Info
- Publication number
- IN2014DN09678A IN2014DN09678A IN9678DEN2014A IN2014DN09678A IN 2014DN09678 A IN2014DN09678 A IN 2014DN09678A IN 9678DEN2014 A IN9678DEN2014 A IN 9678DEN2014A IN 2014DN09678 A IN2014DN09678 A IN 2014DN09678A
- Authority
- IN
- India
- Prior art keywords
- arginase
- activity
- inventive
- compounds
- compositions
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 abstract 2
- 108700024123 Arginases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 abstract 1
- 101710186578 Arginase-2, mitochondrial Proteins 0.000 abstract 1
- 150000001642 boronic acid derivatives Chemical class 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625814P | 2012-04-18 | 2012-04-18 | |
| PCT/US2013/030930 WO2013158262A1 (en) | 2012-04-18 | 2013-03-13 | Ring constrained analogs as arginase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09678A true IN2014DN09678A (de) | 2015-07-31 |
Family
ID=47997937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9678DEN2014 IN2014DN09678A (de) | 2012-04-18 | 2013-03-13 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9200011B2 (de) |
| EP (1) | EP2852598B3 (de) |
| JP (1) | JP6152167B2 (de) |
| CN (1) | CN104540836B (de) |
| AU (1) | AU2013249790B2 (de) |
| BR (1) | BR112014026057B1 (de) |
| CA (1) | CA2870526C (de) |
| HK (1) | HK1209126A1 (de) |
| IL (1) | IL235155B (de) |
| IN (1) | IN2014DN09678A (de) |
| MX (1) | MX355758B (de) |
| WO (1) | WO2013158262A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| BR112013010099B1 (pt) | 2010-10-26 | 2021-08-10 | Mars, Incorporated | Boronatos como inibidores de arginase |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| MA42269A (fr) | 2015-06-23 | 2018-05-02 | Calithera Biosciences Inc | Compositions et procédés d'inhibition de l'activité de l'arginase |
| CA3003271A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| JP6884705B2 (ja) * | 2015-11-18 | 2021-06-09 | 東京応化工業株式会社 | アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法 |
| WO2017085947A1 (ja) * | 2015-11-18 | 2017-05-26 | 東京応化工業株式会社 | アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット及びアルギナーゼ関連疾患検出キット |
| WO2017086421A1 (ja) * | 2015-11-18 | 2017-05-26 | 東京応化工業株式会社 | アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法 |
| PL417066A1 (pl) * | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| JP2020502259A (ja) | 2016-11-08 | 2020-01-23 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ阻害剤併用療法 |
| WO2018090151A1 (es) * | 2016-11-18 | 2018-05-24 | Pontificia Universidad Catolica De Chile | Combinación farmacéutica para el tratamiento y prevención de la hipertensión arterial y disfunción vascular |
| IL292677A (en) | 2016-12-22 | 2022-07-01 | Calithera Biosciences Inc | Preparations and methods for inhibiting arginase activity |
| CN108794517B (zh) * | 2017-04-27 | 2021-03-30 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
| KR20200008578A (ko) * | 2017-05-12 | 2020-01-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법 |
| JP6925163B2 (ja) * | 2017-05-16 | 2021-08-25 | 東京応化工業株式会社 | 尿素の測定方法及び尿素検出キット |
| CN111491937A (zh) * | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
| PE20210176A1 (es) * | 2018-02-17 | 2021-01-29 | Astrazeneca Ab | Inhibidores de arginasa y sus metodos de uso |
| CA3091805A1 (en) | 2018-03-05 | 2019-09-12 | Arcus Biosciences, Inc. | Arginase inhibitors |
| EP3774843B1 (de) | 2018-03-29 | 2022-05-25 | Molecure SA | Dipeptid-piperidinderivate |
| JP7461350B2 (ja) * | 2018-11-16 | 2024-04-03 | アーカス バイオサイエンシーズ インコーポレイテッド | Ａｒｇ１及び／又はａｒｇ２の阻害剤 |
| CN112110944B (zh) * | 2019-06-21 | 2022-02-11 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和应用 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2305703A1 (en) | 1997-10-10 | 1999-04-22 | David W. Christianson | Compositions and methods for inhibiting arginase activity |
| WO2007005620A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Arginase ii: a target treatment of aging heart and heart failure |
| EP2389352B1 (de) | 2009-01-26 | 2019-05-08 | The Trustees Of The University Of Pennsylvania | Arginasehemmer und verwendungsverfahren |
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| BR112013010099B1 (pt) | 2010-10-26 | 2021-08-10 | Mars, Incorporated | Boronatos como inibidores de arginase |
-
2013
- 2013-03-13 EP EP13712088.7A patent/EP2852598B3/de active Active
- 2013-03-13 WO PCT/US2013/030930 patent/WO2013158262A1/en active Application Filing
- 2013-03-13 MX MX2014012606A patent/MX355758B/es active IP Right Grant
- 2013-03-13 CN CN201380028496.7A patent/CN104540836B/zh active Active
- 2013-03-13 CA CA2870526A patent/CA2870526C/en active Active
- 2013-03-13 US US14/391,901 patent/US9200011B2/en active Active
- 2013-03-13 IN IN9678DEN2014 patent/IN2014DN09678A/en unknown
- 2013-03-13 JP JP2015506997A patent/JP6152167B2/ja active Active
- 2013-03-13 AU AU2013249790A patent/AU2013249790B2/en active Active
- 2013-03-13 BR BR112014026057-5A patent/BR112014026057B1/pt active IP Right Grant
-
2014
- 2014-10-19 IL IL235155A patent/IL235155B/en active IP Right Grant
-
2015
- 2015-10-09 HK HK15109890.5A patent/HK1209126A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2852598B3 (de) | 2016-10-19 |
| CN104540836A (zh) | 2015-04-22 |
| MX355758B (es) | 2018-04-27 |
| BR112014026057A2 (pt) | 2017-06-27 |
| IL235155B (en) | 2018-06-28 |
| AU2013249790A1 (en) | 2014-12-04 |
| WO2013158262A1 (en) | 2013-10-24 |
| CA2870526A1 (en) | 2013-10-24 |
| HK1209126A1 (en) | 2016-03-24 |
| US9200011B2 (en) | 2015-12-01 |
| EP2852598A1 (de) | 2015-04-01 |
| US20150080341A1 (en) | 2015-03-19 |
| EP2852598B1 (de) | 2016-05-11 |
| AU2013249790B2 (en) | 2018-01-25 |
| MX2014012606A (es) | 2015-01-19 |
| CA2870526C (en) | 2020-05-05 |
| JP2015516397A (ja) | 2015-06-11 |
| BR112014026057B1 (pt) | 2020-10-13 |
| JP6152167B2 (ja) | 2017-06-21 |
| CN104540836B (zh) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09678A (de) | ||
| MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
| BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
| MX336381B (es) | Boronatos como inhibidores de arginasa. | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| EA201590554A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| MX2015006939A (es) | Tratamiento de cancer con inhibidores heterociclicos de glutaminasa. | |
| EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| MX2013008212A (es) | Derivados de 7-azaindol. | |
| EA201391114A1 (ru) | Способы использования alk-ингибиторов | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| EA201491013A1 (ru) | Пиразиновые ингибиторы киназы | |
| MX2013010840A (es) | Metodos para inhibir c-kit mutante. | |
| PH12016500136B1 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
| UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| MD20140001A2 (ro) | Modulatori alosterici pozitivi ai receptorului nicotinic al acetilcolinei | |
| CR20140289A (es) | Derivados de quinolina como inhibidores de la enzima pde10a | |
| EA201270188A1 (ru) | Способ прогнозирования увеличения массы тела, связанного с фармацевтической терапией |